4.8 Article

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

Journal

NATURE COMMUNICATIONS
Volume 6, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/ncomms7336

Keywords

-

Funding

  1. Cancer Research UK [CR-UK A/16459]
  2. U-Care
  3. Genomic Medicine Theme of the Oxford NIHR Comprehensive Biomedical Research Centre
  4. Spanish Ministerio de Economia y Competitividad
  5. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  6. Krebsliga beider Basel [11-2011]
  7. Krebsliga Zentralschweiz
  8. Wellcome Trust Centre for Human Genetics from the Wellcome Trust [090532/Z/09/Z]
  9. European Union Framework 7 PREDICT, RESPONSIFY
  10. European Research Council (THESEUS) grants
  11. Breast Cancer Research Foundation
  12. Prostate Cancer Research Foundation
  13. Rosetrees Trust
  14. EU ERC EVOCAN award
  15. RMH/ICR NIHR Biomedical Research Centre for Cancer
  16. Academy of Medical Sciences (AMS) [AMS-SGCL2-Tran] Funding Source: researchfish
  17. Cancer Research UK [19310, 17786] Funding Source: researchfish
  18. Rosetrees Trust [M179] Funding Source: researchfish
  19. The Francis Crick Institute [10174, 10170, 10359, 10172, 10002, 10001, 10303, 10169] Funding Source: researchfish

Ask authors/readers for more resources

Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behaviour. Here we sequence the genomes or exomes of 31 pRCCs, and in four tumours, multi-region sequencing is undertaken. We identify BAP1, SETD2, ARID2 and Nrf2 pathway genes (KEAP1, NHE2L2 and CUL3) as probable drivers, together with at least eight other possible drivers. However, only similar to 10% of tumours harbour detectable pathogenic changes in any one driver gene, and where present, the mutations are often predicted to be present within cancer sub-clones. We specifically detect parallel evolution of multiple SETD2 mutations within different sub-regions of the same tumour. By contrast, large copy number gains of chromosomes 7, 12, 16 and 17 are usually early, monoclonal changes in pRCC evolution. The predominance of large copy number variants as the major drivers for pRCC highlights an unusual mode of tumorigenesis that may challenge precision medicine approaches.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available